FI973309A0 - Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi - Google Patents

Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi

Info

Publication number
FI973309A0
FI973309A0 FI973309A FI973309A FI973309A0 FI 973309 A0 FI973309 A0 FI 973309A0 FI 973309 A FI973309 A FI 973309A FI 973309 A FI973309 A FI 973309A FI 973309 A0 FI973309 A0 FI 973309A0
Authority
FI
Finland
Prior art keywords
producing
recombinant adenovirus
adenovirus genome
adenoviruses
disclosed
Prior art date
Application number
FI973309A
Other languages
English (en)
Swedish (sv)
Other versions
FI120046B (fi
FI973309A (fi
Inventor
Joel Crouzet
Laurent Naudin
Cecile Orsini
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI973309(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI973309A publication Critical patent/FI973309A/fi
Publication of FI973309A0 publication Critical patent/FI973309A0/fi
Application granted granted Critical
Publication of FI120046B publication Critical patent/FI120046B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI973309A 1995-02-13 1997-08-12 Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi FI120046B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9501632 1995-02-13
FR9501632A FR2730504B1 (fr) 1995-02-13 1995-02-13 Procede de preparation de genomes d'adenovirus recombinants
FR9600215 1996-01-10
PCT/FR1996/000215 WO1996025506A1 (fr) 1995-02-13 1996-02-09 Procede de preparation de genome d'adenovirus recombinants

Publications (3)

Publication Number Publication Date
FI973309A FI973309A (fi) 1997-08-12
FI973309A0 true FI973309A0 (fi) 1997-08-12
FI120046B FI120046B (fi) 2009-06-15

Family

ID=9476085

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973309A FI120046B (fi) 1995-02-13 1997-08-12 Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi

Country Status (19)

Country Link
US (1) US6261807B1 (fi)
EP (1) EP0809704B1 (fi)
JP (1) JP3842818B2 (fi)
KR (1) KR100575521B1 (fi)
AT (1) ATE405662T1 (fi)
AU (1) AU716777B2 (fi)
BR (1) BRPI9607583B8 (fi)
CA (1) CA2210956C (fi)
CZ (1) CZ294338B6 (fi)
DE (1) DE69637648D1 (fi)
FI (1) FI120046B (fi)
FR (1) FR2730504B1 (fi)
HU (1) HU222808B1 (fi)
IL (1) IL117115A (fi)
MX (1) MX9705937A (fi)
NO (1) NO327980B1 (fi)
SK (1) SK286965B6 (fi)
WO (1) WO1996025506A1 (fi)
ZA (1) ZA961153B (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136708A1 (en) * 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
ATE256196T1 (de) 1997-06-09 2003-12-15 Genvec Inc Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
WO1999015686A1 (en) * 1997-09-23 1999-04-01 Genvec, Inc. Plasmids for construction of eukaryotic viral vectors
CN1342206A (zh) * 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
JP2004501602A (ja) * 1999-02-18 2004-01-22 メルク アンド カンパニー インコーポレイテッド エンドヌクレアーゼの使用に基づくヘルパー依存アデノウイルスベクターの生産のためのシステム
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
US6998263B2 (en) 2000-02-09 2006-02-14 Genvec, Inc. Methods of preparing and using a viral vector library
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
EP2147105B1 (en) 2007-05-02 2013-04-24 Merial Limited Dna plasmids having improved expression and stability
US20110269119A1 (en) * 2009-10-30 2011-11-03 Synthetic Genomics, Inc. Encoding text into nucleic acid sequences
AU2014338864C1 (en) * 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
US10076562B2 (en) 2016-04-19 2018-09-18 The Board Of Regents Of The University Of Texas System Methods for treating plague
WO2018054822A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
NZ751966A (en) 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New promoters
TWI817933B (zh) 2016-09-20 2023-10-11 德商百靈佳殷格翰維美迪加股份有限公司 新穎ehv插入位點orf70
TW201823467A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 犬腺病毒載體

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3532566B2 (ja) * 1993-06-24 2004-05-31 エル. グラハム,フランク 遺伝子治療のためのアデノウイルスベクター
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
DK0787200T3 (da) * 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral

Also Published As

Publication number Publication date
SK110097A3 (en) 1998-06-03
CA2210956C (fr) 2010-06-08
IL117115A0 (en) 1996-06-18
FI120046B (fi) 2009-06-15
JP3842818B2 (ja) 2006-11-08
MX9705937A (es) 1997-10-31
JPH11500007A (ja) 1999-01-06
CA2210956A1 (fr) 1996-08-22
AU716777B2 (en) 2000-03-09
NO327980B1 (no) 2009-11-02
NO973663L (no) 1997-08-08
BRPI9607583B8 (pt) 2016-11-08
BR9607583B1 (pt) 2009-12-01
HUP9800260A3 (en) 2000-12-28
HU222808B1 (hu) 2003-10-28
US6261807B1 (en) 2001-07-17
SK286965B6 (sk) 2009-08-06
AU4723596A (en) 1996-09-04
FI973309A (fi) 1997-08-12
CZ294338B6 (cs) 2004-12-15
KR19980702139A (ko) 1998-07-15
FR2730504A1 (fr) 1996-08-14
WO1996025506A1 (fr) 1996-08-22
NO973663D0 (no) 1997-08-08
BR9607583A (pt) 1998-07-07
IL117115A (en) 2005-06-19
HUP9800260A1 (hu) 1998-05-28
ATE405662T1 (de) 2008-09-15
EP0809704B1 (fr) 2008-08-20
KR100575521B1 (ko) 2006-10-24
CZ255497A3 (en) 1997-11-12
ZA961153B (en) 1996-08-23
DE69637648D1 (de) 2008-10-02
FR2730504B1 (fr) 1997-03-28
EP0809704A1 (fr) 1997-12-03

Similar Documents

Publication Publication Date Title
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
AU641568B2 (en) Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
ATE304058T1 (de) Rekombinante mva viren und deren verwendung
NO950939L (no) Defektive adenovirusvektorer og deres anvendelse i gene-terapien
ATE237694T1 (de) Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
ATE177473T1 (de) Herstellung von rekombinanten, menschlichem lactoferrin
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
DE69637856D1 (en) Interleukin-19.
MX9601368A (es) Metodo de tratamiento de la reestenosis por terapia genica.
FI962114A (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
AU6144494A (en) Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
DE59408697D1 (de) Multicistronische expression rekombinanter gene in bakterienzellen
DE69531678D1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
AU588996B2 (en) N-(2'-aminophenyl)-benzamine-derivatives, process for their preparation and their use in the control of neoplastic diseases
AU1209797A (en) Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same
MX9708877A (es) P62, sus variantes, las secuencias de acidos nucleicos que los codifican, y su utilizacion en terapia genica anti-cancerosa.
AU5259896A (en) Recombinant rna viral vector and method of preparing the same
ZA872829B (en) N-(2'-aminophenyl)-benzamide-derivatives,process for their preparation and their use in the control of neoplastic diseases

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120046

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: AVENTIS PHARMA S.A.

Free format text: AVENTIS PHARMA S.A.

MA Patent expired